 LEEDS, England--BUSINESS WIRE--4D pharma plc AIM: DDD, a pharmaceutical company leading the development of Live Biotherapeutic products LBPs - a novel class of drug derived from the microbiome, today announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier will also be a member of 4Ds Audit and Risk Committee and will serve as the Companys audit committee financial expert under SEC and Nasdaq rules. With over 25 years of extensive senior operational, 